Marksans Pharma Limited Q4 FY26 Results: PAT Jumps 64% To Reach ₹149 Crore

Marksans Pharma Limited reported its highest-ever quarterly and annual financial performance for FY26, helped by strong growth across the US, UK and Australia businesses along with multiple product launches during the year.

For Q4 FY26, consolidated net income stood at ₹891.3 crore, rising 23.1% year-on-year (YoY) from ₹723.8 crore in Q4 FY25. Net income also increased 15.1% sequentially from ₹774.6 crore in Q3 FY26.

On the National Stock Exchange, Marksans Pharma’s share price had surged almost 16% to reach ₹254.79 at the close of the market on 26 May 2026.

Marksans Pharma’s Q4 Performance Highlights

Operating revenue for the March quarter came in at ₹856.1 crore, up 20.8% YoY and 13.5% QoQ. Gross profit rose 21.5% to ₹465.5 crore compared to ₹383.2 crore in the year-ago quarter, while gross margin improved slightly to 54.4% from 54.1%.

The company reported a sharp improvement in operating profitability during the quarter. EBITDA increased 54% YoY to ₹195.4 crore from ₹126.9 crore, while EBITDA margin expanded 491 basis points to 22.8% from 17.9% last year. Sequentially, EBITDA rose 21.6% from ₹160.7 crore in Q3 FY26.

Profit after tax for Q4 FY26 stood at ₹149 crore, jumping 64.3% year-on-year from ₹90.7 crore and rising 31.1% quarter-on-quarter from ₹113.7 crore. Net profit margin improved to 16.7% from 12.5% in Q4 FY25. Earnings per share increased to ₹3.3 from ₹2.0 a year ago.

FY26 Financial Summary

For the full FY26 period, consolidated net income rose 12.8% to ₹3,033.5 crore from ₹2,689.2 crore in FY25. EBITDA increased 12.8% to ₹600.8 crore, while PAT rose 9.8% to ₹420.1 crore. EBITDA margin remained stable at 20.4%.

Marksans Pharma ended FY26 with a cash balance of around ₹990 crore. Cash generated from operations stood at ₹458 crore during the year, while net capex incurred was ₹131 crore. R&D spending for FY26 came in at ₹89 crore, equivalent to 3% of consolidated revenue.

Also Read - Astra Microwave Products Limited Q4 FY26 Results: Profit Jumps 44% On Strong Defence Orders

The US and North America business remained the company’s largest market. Revenue from the segment stood at ₹406 crore during Q4 FY26 and ₹1,533 crore for the full year.

The board recommended a final dividend of ₹0.90 per share for FY26, subject to approval in its upcoming board meeting.

Source:

Company Press Release